{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:38:25Z","timestamp":1789403905097,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DP1DA054344"],"award-info":[{"award-number":["DP1DA054344"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-19079-01-TBG"],"award-info":[{"award-number":["RSG-19079-01-TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04081-5","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T07:29:39Z","timestamp":1748590179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Inhibition of head and neck squamous cell carcinoma by Bruton\u2019s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells"],"prefix":"10.1007","volume":"74","author":[{"given":"Anna R.","family":"Bopp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe F.","family":"Lamenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja","family":"Upadhaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan M.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Kazmierowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete P.","family":"Jordanides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arham","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherefuddin H.","family":"Pracha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyton","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. Hans","family":"Iwenofu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Oghumu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"5","key":"4081_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.trecan.2018.03.006","volume":"4","author":"RT Santuray","year":"2018","unstructured":"Santuray RT, Johnson DE, Grandis JR (2018) New therapies in head and neck cancer. Trends Cancer 4(5):385\u2013396","journal-title":"Trends Cancer"},{"issue":"1","key":"4081_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6(1):92","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"4081_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","volume":"7","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL et al (2019) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 7(1):184","journal-title":"J Immunother Cancer"},{"issue":"Pt 2","key":"4081_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.semcancer.2018.01.008","volume":"52","author":"B Solomon","year":"2018","unstructured":"Solomon B, Young RJ, Rischin D (2018) Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol 52(Pt 2):228\u2013240","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"4081_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/cancers13020338","volume":"13","author":"J Muzaffar","year":"2021","unstructured":"Muzaffar J, Bari S, Kirtane K, Chung CH (2021) Recent advances and future directions in clinical management of head and neck squamous cell carcinoma. Cancers 13(2):338","journal-title":"Cancers"},{"key":"4081_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.668996","volume":"9","author":"X Wang","year":"2021","unstructured":"Wang X, Kokabee L, Kokabee M, Conklin DS (2021) Bruton\u2019s tyrosine kinase and its isoforms in cancer. Front Cell Dev Biol 9:668996","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"4081_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","volume":"25","author":"JA Burger","year":"2019","unstructured":"Burger JA (2019) Bruton tyrosine kinase inhibitors: present and future. Cancer J 25(6):386\u2013393","journal-title":"Cancer J"},{"issue":"2","key":"4081_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","volume":"35","author":"T Wen","year":"2021","unstructured":"Wen T, Wang J, Shi Y, Qian H, Liu P (2021) Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances. Leukemia 35(2):312\u2013332","journal-title":"Leukemia"},{"issue":"8","key":"4081_CR9","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/cells11081338","volume":"11","author":"K Szklener","year":"2022","unstructured":"Szklener K, Michalski A, \u017bak K, Piwo\u0144ski M, Ma\u0144dziuk S (2022) Ibrutinib in the treatment of solid tumors: current state of knowledge and future directions. Cells 11(8):1338","journal-title":"Cells"},{"issue":"1","key":"4081_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW (2018) Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer 17(1):57","journal-title":"Mol Cancer"},{"issue":"4","key":"4081_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP (2014) Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer 14(4):219\u2013232","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"4081_CR12","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1080\/15384047.2015.1078023","volume":"16","author":"L Kokabee","year":"2015","unstructured":"Kokabee L, Wang X, Sevinsky CJ, Wang WL, Cheu L, Chittur SV, Karimipoor M, Tenniswood M, Conklin DS (2015) Bruton\u2019s tyrosine kinase is a potential therapeutic target in prostate cancer. Cancer Biol Ther 16(11):1604\u20131615","journal-title":"Cancer Biol Ther"},{"issue":"15","key":"4081_CR13","doi-asserted-by":"publisher","first-page":"13255","DOI":"10.18632\/oncotarget.3658","volume":"6","author":"MA Zucha","year":"2015","unstructured":"Zucha MA, Wu AT, Lee WH, Wang LS, Lin WW, Yuan CC, Yeh CT (2015) Bruton\u2019s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Oncotarget 6(15):13255\u201313268","journal-title":"Oncotarget"},{"issue":"1","key":"4081_CR14","doi-asserted-by":"publisher","first-page":"e005425","DOI":"10.1136\/jitc-2022-005425","volume":"11","author":"M Sinha","year":"2023","unstructured":"Sinha M, Betts C, Zhang L, Griffith MJ, Solman I, Chen B, Liu E, Tamaki W, Stultz J, Marquez J et al (2023) Modulation of myeloid and T cells in vivo by Bruton\u2019s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. J Immunother Cancer 11(1):e005425","journal-title":"J Immunother Cancer"},{"issue":"7","key":"4081_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41416-020-0743-8","volume":"122","author":"S Varikuti","year":"2020","unstructured":"Varikuti S, Singh B, Volpedo G, Ahirwar DK, Jha BK, Saljoughian N, Viana AG, Verma C, Hamza O, Halsey G et al (2020) Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells. Br J Cancer 122(7):1005\u20131013","journal-title":"Br J Cancer"},{"issue":"10","key":"4081_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/gcc.22091","volume":"52","author":"C Eifert","year":"2013","unstructured":"Eifert C, Wang X, Kokabee L, Kourtidis A, Jain R, Gerdes MJ, Conklin DS (2013) A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. Genes Chromosomes Cancer 52(10):961\u2013975","journal-title":"Genes Chromosomes Cancer"},{"issue":"6","key":"4081_CR17","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cancers11060880","volume":"11","author":"D Basile","year":"2019","unstructured":"Basile D, Gerratana L, Buonadonna A, Garattini SK, Perin T, Grassilli E, Miolo G, Cerrito MG, Belluco C, Bertola G et al (2019) Role of Bruton\u2019s tyrosine kinase in stage III colorectal cancer. Cancers 11(6):880","journal-title":"Cancers"},{"key":"4081_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.690365","volume":"9","author":"E Grassilli","year":"2021","unstructured":"Grassilli E, Cerrito MG, Bonomo S, Giovannoni R, Conconi D, Lavitrano M (2021) p65BTK is a novel biomarker and therapeutic target in solid tumors. Front Cell Dev Biol 9:690365","journal-title":"Front Cell Dev Biol"},{"key":"4081_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fnmol.2019.00002","volume":"12","author":"L Sala","year":"2019","unstructured":"Sala L, Cirillo G, Riva G, Romano G, Giussani C, Cialdella A, Todisco A, Virtuoso A, Cerrito MG, Bentivegna A et al (2019) Specific expression of a new Bruton tyrosine kinase isoform (p65BTK) in the glioblastoma gemistocytic histotype. Front Mol Neurosci 12:2","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"4081_CR20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13046-019-1199-7","volume":"38","author":"F Giordano","year":"2019","unstructured":"Giordano F, Vaira V, Cortinovis D, Bonomo S, Goedmakers J, Brena F, Cialdella A, Ianzano L, Forno I, Cerrito MG et al (2019) p65BTK is a novel potential actionable target in KRAS-mutated\/EGFR-wild type lung adenocarcinoma. J Exp Clin Cancer Res 38(1):260","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4081_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/cancers15010310","volume":"15","author":"AC Betzler","year":"2023","unstructured":"Betzler AC, Strobel H, Abou Kors T, Ezi\u0107 J, Lesakova K, Pscheid R, Azoitei N, Sporleder J, Staufenberg AR, Drees R et al (2023) BTK isoforms p80 and p65 are expressed in head and neck squamous cell carcinoma (HNSCC) and involved in tumor progression. Cancers 15(1):310","journal-title":"Cancers"},{"issue":"2","key":"4081_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41389-021-00308-z","volume":"10","author":"SC Liu","year":"2021","unstructured":"Liu SC, Wu YC, Huang CM, Hsieh MS, Huang TY, Huang CS, Hsu TN, Huang MS, Lee WH, Yeh CT et al (2021) Inhibition of Bruton\u2019s tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness. Oncogenesis 10(2):20","journal-title":"Oncogenesis"},{"issue":"7","key":"4081_CR23","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00262-020-02535-6","volume":"69","author":"SS Jeske","year":"2020","unstructured":"Jeske SS, Brand M, Ziebart A, Laban S, Doescher J, Greve J, Jackson EK, Hoffmann TK, Brunner C, Schuler PJ (2020) Adenosine-producing regulatory B cells in head and neck cancer. Cancer Immunol Immunother 69(7):1205\u20131216","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"4081_CR24","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1158\/1078-0432.CCR-21-2547","volume":"28","author":"MH Taylor","year":"2022","unstructured":"Taylor MH, Betts CB, Maloney L, Nadler E, Algazi A, Guarino MJ, Nemunaitis J, Jimeno A, Patel P, Munugalavadla V et al (2022) Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: phase 2 proof-of-concept study. Clin Cancer Res 28(5):903\u2013914","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4081_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Liu C, Tsui ST, Liu D (2016) Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol 9(1):80","journal-title":"J Hematol Oncol"},{"key":"4081_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.650414","volume":"9","author":"FM Uckun","year":"2021","unstructured":"Uckun FM, Venkatachalam T (2021) Targeting solid tumors with BTK inhibitors. Front Cell Dev Biol 9:650414","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"4081_CR27","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/imm.13416","volume":"164","author":"C McDonald","year":"2021","unstructured":"McDonald C, Xanthopoulos C, Kostareli E (2021) The role of Bruton\u2019s tyrosine kinase in the immune system and disease. Immunology 164(4):722\u2013736","journal-title":"Immunology"},{"key":"4081_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ctrv.2017.06.001","volume":"58","author":"J Molina-Cerrillo","year":"2017","unstructured":"Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E (2017) Bruton\u2019s tyrosine kinase (BTK) as a promising target in solid tumors. Cancer Treat Rev 58:41\u201350","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"4081_CR29","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3390\/cancers13050953","volume":"13","author":"K Anderson","year":"2021","unstructured":"Anderson K, Ryan N, Alkhimovitch A, Siddiqui A, Oghumu S (2021) Inhibition of PI3K isoform p110\u03b3 increases both anti-tumor and immunosuppressive responses to aggressive murine head and neck squamous cell carcinoma with low immunogenicity. Cancers 13(5):953","journal-title":"Cancers"},{"key":"4081_CR30","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.3389\/fimmu.2019.03095","volume":"10","author":"K Anderson","year":"2019","unstructured":"Anderson K, Ryan N, Volpedo G, Varikuti S, Satoskar AR, Oghumu S (2019) Immune suppression mediated by STAT4 deficiency promotes lymphatic metastasis in HNSCC. Front Immunol 10:3095","journal-title":"Front Immunol"},{"issue":"7","key":"4081_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167345","volume":"1870","author":"N Ryan","year":"2024","unstructured":"Ryan N, Lamenza F, Shrestha S, Upadhaya P, Springer A, Jordanides P, Pracha H, Roth P, Kumar R, Wang Y et al (2024) Host derived macrophage migration inhibitory factor expression attenuates anti-tumoral immune cell accumulation and promotes immunosuppression in the tumor microenvironment of head and neck squamous cell carcinoma. Biochim Biophys Acta Mol Basis Dis 1870(7):167345","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"13","key":"4081_CR32","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.3390\/cancers15133334","volume":"15","author":"P Upadhaya","year":"2023","unstructured":"Upadhaya P, Ryan N, Roth P, Pero T, Lamenza F, Springer A, Jordanides P, Pracha H, Mitchell D, Oghumu S (2023) Ionizing radiation reduces head and neck squamous cell carcinoma cell viability and is associated with predictive tumor-specific T cell responses. Cancers 15(13):3334","journal-title":"Cancers"},{"issue":"1","key":"4081_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/carcin\/bgab118","volume":"43","author":"D Nedungadi","year":"2022","unstructured":"Nedungadi D, Ryan N, Anderson K, Lamenza FF, Jordanides PP, Swingler MJ, Rakotondraibe L, Riedl KM, Iwenofu H, Oghumu S (2022) Modulation of the oral glucocorticoid system during black raspberry mediated oral cancer chemoprevention. Carcinogenesis 43(1):28\u201339","journal-title":"Carcinogenesis"},{"key":"4081_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.107126","volume":"160","author":"SH Pracha","year":"2025","unstructured":"Pracha SH, Shrestha S, Ryan N, Upadhaya P, Lamenza FF, Jagadeesha S, Jordanides P, Roth P, Springer A, Oghumu S (2025) Targeting macrophage migration inhibitory factor to inhibit T cell immunosuppression in the tumor microenvironment and improve cancer outcomes in head and neck squamous cell carcinoma. Oral Oncol 160:107126","journal-title":"Oral Oncol"},{"issue":"4","key":"4081_CR35","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41416-022-01853-z","volume":"127","author":"K Anderson","year":"2022","unstructured":"Anderson K, Ryan N, Nedungadi D, Lamenza F, Swingler M, Siddiqui A, Satoskar A, Upadhaya P, Pietrzak M, Oghumu S (2022) STAT1 is regulated by TRIM24 and promotes immunosuppression in head and neck squamous carcinoma cells, but enhances T cell antitumour immunity in the tumour microenvironment. Br J Cancer 127(4):624\u2013636","journal-title":"Br J Cancer"},{"key":"4081_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.932742","volume":"13","author":"NM Ryan","year":"2022","unstructured":"Ryan NM, Lamenza FF, Upadhaya P, Pracha H, Springer A, Swingler M, Siddiqui A, Oghumu S (2022) Black raspberry extract inhibits regulatory T-cell activity in a murine model of head and neck squamous cell carcinoma chemoprevention. Front Immunol 13:932742","journal-title":"Front Immunol"},{"key":"4081_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110133","volume":"128","author":"B Tan","year":"2020","unstructured":"Tan B, Huang Y, Zhang B, Lin N (2020) The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR\/AKT\/mTOR signaling pathway. Biomed Pharmacother 128:110133","journal-title":"Biomed Pharmacother"},{"issue":"17","key":"4081_CR38","doi-asserted-by":"publisher","first-page":"13133","DOI":"10.3390\/ijms241713133","volume":"24","author":"F Leichtle","year":"2023","unstructured":"Leichtle F, Betzler AC, Eizenberger C, Lesakova K, Ezi\u0107 J, Drees R, Greve J, Schuler PJ, Laban S, Hoffmann TK et al (2023) Influence of Bruton\u2019s tyrosine kinase (BTK) on epithelial-mesenchymal transition (EMT) processes and cancer stem cell (CSC) enrichment in head and neck squamous cell carcinoma (HNSCC). Int J Mol Sci 24(17):13133","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"4081_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.mrrev.2011.05.002","volume":"728","author":"F van Zijl","year":"2011","unstructured":"van Zijl F, Krupitza G, Mikulits W (2011) Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res 728(1\u20132):23\u201334","journal-title":"Mutat Res"},{"issue":"6","key":"4081_CR40","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3390\/cancers15061642","volume":"15","author":"K Starska-Kowarska","year":"2023","unstructured":"Starska-Kowarska K (2023) The role of different immunocompetent cell populations in the pathogenesis of head and neck cancer-regulatory mechanisms of pro- and anti-cancer activity and their impact on immunotherapy. Cancers 15(6):1642","journal-title":"Cancers"},{"issue":"9","key":"4081_CR41","doi-asserted-by":"publisher","first-page":"E966","DOI":"10.1073\/pnas.1500712112","volume":"112","author":"I Sagiv-Barfi","year":"2015","unstructured":"Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R (2015) Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci USA 112(9):E966-972","journal-title":"Proc Natl Acad Sci USA"},{"key":"4081_CR42","doi-asserted-by":"publisher","first-page":"715234","DOI":"10.3389\/fimmu.2021.715234","volume":"12","author":"JS Dolina","year":"2021","unstructured":"Dolina JS, Van Braeckel-Budimir N, Thomas GD, Salek-Ardakani S (2021) CD8. Front Immunol 12:715234","journal-title":"Front Immunol"},{"issue":"3","key":"4081_CR43","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.immuni.2020.08.005","volume":"53","author":"N Acharya","year":"2020","unstructured":"Acharya N, Madi A, Zhang H, Klapholz M, Escobar G, Dulberg S, Christian E, Ferreira M, Dixon KO, Fell G et al (2020) Endogenous glucocorticoid signaling regulates CD8. Immunity 53(3):658-671.e656","journal-title":"Immunity"},{"key":"4081_CR44","doi-asserted-by":"publisher","first-page":"1201415","DOI":"10.3389\/fimmu.2023.1201415","volume":"14","author":"L Li","year":"2023","unstructured":"Li L, Zhao M, Kiernan CH, Castro Eiro MD, van Meurs M, Brouwers-Haspels I, Wilmsen MEP, Grashof DGB, van de Werken HJG, Hendriks RW et al (2023) Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK. Front Immunol 14:1201415","journal-title":"Front Immunol"},{"issue":"8","key":"4081_CR45","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/JCI89756","volume":"127","author":"M Long","year":"2017","unstructured":"Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM et al (2017) Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Investig 127(8):3052\u20133064","journal-title":"J Clin Investig"},{"issue":"3","key":"4081_CR46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/sji.12333","volume":"82","author":"A Bergl\u00f6f","year":"2015","unstructured":"Bergl\u00f6f A, Hamasy A, Meinke S, Palma M, Krstic A, M\u00e5nsson R, Kimby E, \u00d6sterborg A, Smith CI (2015) Targets for ibrutinib beyond B cell malignancies. Scand J Immunol 82(3):208\u2013217","journal-title":"Scand J Immunol"},{"issue":"4","key":"4081_CR47","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR et al (2016) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):323\u2013332","journal-title":"N Engl J Med"},{"issue":"48","key":"4081_CR48","doi-asserted-by":"publisher","first-page":"7990","DOI":"10.1038\/sj.onc.1208074","volume":"23","author":"EH Palacios","year":"2004","unstructured":"Palacios EH, Weiss A (2004) Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23(48):7990\u20138000","journal-title":"Oncogene"},{"issue":"7","key":"4081_CR49","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","volume":"21","author":"L Liu","year":"2015","unstructured":"Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson C et al (2015) The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 21(7):1639\u20131651","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4081_CR50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","volume":"22","author":"V Verma","year":"2021","unstructured":"Verma V, Jafarzadeh N, Boi S, Kundu S, Jiang Z, Fan Y, Lopez J, Nandre R, Zeng P, Alolaqi F et al (2021) MEK inhibition reprograms CD8. Nat Immunol 22(1):53\u201366","journal-title":"Nat Immunol"},{"issue":"9","key":"4081_CR51","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00262-021-02908-5","volume":"70","author":"L Good","year":"2021","unstructured":"Good L, Benner B, Carson WE (2021) Bruton\u2019s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment. Cancer Immunol Immunother 70(9):2439\u20132451","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"4081_CR52","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1158\/0008-5472.CAN-15-1490","volume":"76","author":"A Stiff","year":"2016","unstructured":"Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, McMichael E, Duggan M, Campbell A, Keller K et al (2016) Myeloid-derived suppressor cells express Bruton\u2019s tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment. Cancer Res 76(8):2125\u20132136","journal-title":"Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04081-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04081-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04081-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T18:01:34Z","timestamp":1749924094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04081-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4081"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04081-5","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"227"}}